Skip to main content
OpenTrials
Completed

NCT Number: NCT06908837

Effects of 10 Versus 20 mL Local Anesthetic for Popliteal Plexus Block on Opioid Consumption, Pain, and Patient-Reported Outcomes After Total Knee Arthroplasty

This trial aims to assess the analgesic effect of Popliteal Plexus Block (PPB) with 10 mL versus 20 mL of Bupivacain 5 mg/mL, when applied as an adjunct treatment to a multimodal analgesic regimen following primary total knee arthroplasty. We hypothesize that PPB with 20 mL of local anesthetic reduces 24-hour postoperative opioid consumption (= primary outcome) compared to 10 mL after TKA.

Secondary outcome include

* the frequency of 24-hour opioid-free analgesia * pain intensity at rest and during mobilization * Manual Muscle Tests and ability to mobilize with crutches six hours after end-of-surgery * and patients reported outcomes using the Quality of Recovery 15 survey 24 hours after end-of-surgery.

Participant will:

* undergo primary total knee arthroplasty in spinal anesthesia. * recieve a PPB with either 10 mL of Bupivacaine or 20 mL. * recieve a multimodal analgesic regime including a Femoral Triangle Block. * Have 10 scored morphine tablets available for self-administration within the first 24 postoperative hours after end-of-surgery. * be examined by a physiotherapist 6 hours (±1 hour) after end-of-surgery to assess pain scores, manual muscle testing of ankle and knee function, and the ability to mobilize with crutches. * complete a survey 24 hours after end-of-surgery to assess self-administered morphine intake, pain scores, and Quality of Recovery-15.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Elective Surgery Centre at Silkeborg Regional Hospital

Silkeborg, Denmark Central Region, 8600, Denmark

About this study

Patients will undergo primary unilateral total knee arthroplasty with insertion of non-cruciate retaining standard cemented prosthesis by a parapatellar medial approach, without use of tourniquet or Local Infiltration Analgesia.

For the spinal anesthesia, 3 mL of Ropivacaine 5 mg/ml will be applied.

All patients will receive a femoral triangle block in combination with the PPB, both administered immediately after surgery in the post-anesthesia care unit.

Description of the PPB procedure:

The superficial femoral artery is identified at mid-thigh level and traced caudally until it deviates from sartorius muscle and is positioned adjacent to the posteromedial margin of the vastus medialis muscle, close to the adductor hiatus. The needle will be inserted medially to the transducer and advanced in-plane through the sartorius muscle targeting the endpoint of injection in the distal part of the adductor canal, on the top of the superficial femoral artery, posteromedial to the fascia of the vastus medialis muscle. We will inject the allocated volume of bupivacaine 5 mg/mL, ensuring anterolaterally spread to the artery

The Femoral Triangle Block uses 15 mL of Bupivacaine 5 mg/mL (10 mL applied in the femoral triangle to target the saphenous nerve and nerve to vastus medialis and 5 mL applied to target the intermediate femoral cutaneous nerve located at the superficial side of the sartorius muscle).

The multimodal analgesic regime also consists of a Dexamethasone 12 mg IV (administered perioperatively), Paracetamol (1000 mg) x 4 daily + NSAID (400 mg) x 3 times daily postoperatively, inclusing preoperatively administration of Paracetamol 1000 mg and Ibuprofen 400 mg.

The scored morphine tablets allows the patients to take 5 mg morphine at a time, with a maximum oral dose of 100 mg within the first 24 hours after end-of-surgery time. If needed, hospital staff can administer rescue doses of intravenous morphine, which will be recorded in the patient file. Total opioid consumption will be reported as oral morphine milligram equivalents (MME), combining hospital-administered opioid doses from the patient file and self-reported intake of dispensed morphine tablets.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Scheduled to undergo primary total knee arthroplasty in spinal anesthesia.
  • Ability to give their written informed consent after having fully understood the contents of the study.
  • American Society of Anesthesiologists (ASA) physical status 1, 2, or 3.

Exclusion criteria

  • Patients who cannot read or speak Danish.
  • Patients who cannot operate or have access to a smartphone with internet connectivity (required for patient-reported outcome assessment).
  • Patients with allergies or intolerance to the medicines used in the study.
  • Patients with a consistent daily intake of opioids preoperatively.
  • Patients who are dependent on walking aid devices preoperatively.
  • Patients suffering from alcohol and/or drug abuse - based on the investigator's assessment.
  • BMI > 40.
  • Diagnosed with chronic neurodegenerative disorders.

Treatment and study plan

Bupivacaine

Drug

Applied perineurally using a 22-gauge, 80-mm block needle (Temena, Felsberg, Germany) under ultrasound guidance.

Primary outcomes

  1. Total opioid consumption, expressed in oral morphine milligram equivalents (MME).

    Time frame: From T0 (end-of-surgery time) to T24 (24 hours after end-of-surgery time)

    Combining hospital-administered opioid doses from the patient file and self-reported intake of dispensed morphine tablets.

Secondary outcomes

  1. No opioid requirement

    Time frame: From T0 (end-of-surgery time) to T24 (24 hours after end-of-surgery time)

    The frequency of patients with no opioid consumption

  2. Pain at rest

    Time frame: Assessed preoperatively, at T6 (6±1 hours after end-of-surgery time), and at T24 (24 hours after end-of-surgery time).

    Registered using the Numeric Rating Scale (0 = no pain and 10 = worst imaginable pain)

  3. Pain during 10 meters walk assisted only by crutches

    Time frame: Assessed preoperatively, at T6 (6±1 hours after end-of-surgery time), and at T24 (24 hours after end-of-surgery time).

    Registered using the Numeric Rating Scale (0 = no pain and 10 = worst imaginable pain)

  4. Early postoperative walking ability

    Time frame: Assessed at T6 (6±1 end-of-surgery time)

    The frequency of patients unable to walk 10 meters with crutches at T6

  5. Postoperative Manual Muscle Test

    Time frame: Assessed at T6 (6±1 end-of-surgery time)

    Frequency of patients with Manual Muscle Test results < Grade 3 in evaluations of dorsiflexion and plantarflexion of the ankle and knee extension.

    Grade 5: Patient can move the limb in the intended direction against gravity and maximum manual resistance. Grade 4: Patient can move the limb in the intended direction against gravity and moderate manual resistance. Grade 3: Patient can move the limb in the intended direction against gravity without resistance. Grade 2: Patient can move the limb in the intended direction only by elimination of the gravity or with minimal assistance from the investigator. Grade 1: Patient is unable to move the limb in the intended direction, but muscle contraction of the respective muscle is palpable or observable. Grade 0: No muscle contraction of the respective muscle is palpable or observable.

  6. Quality of Recovery 15

    Time frame: Assessed at T24 (24 hours after end-of-surgery time)

    Patient reported outcome measure of the Quality of Recovery 15 survey.

Sponsors and collaborators

Lead sponsor

Regionshospitalet Silkeborg

Other

Registry information

Official study title

Effects of 10 Versus 20 mL Local Anesthetic for Popliteal Plexus Block on Opioid Consumption, Pain, and Patient-Reported Outcomes After Total Knee Arthroplasty - a Randomized, Controlled, Blinded Study

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Apr 3, 2025
Registry last updated
Jan 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.